Tirzepatide vs MOTS-c
A detailed side-by-side comparison of Tirzepatide and MOTS-c covering dosing, storage, research findings, and practical usage.
Overview
Tirzepatide: A dual GIP and GLP-1 receptor agonist for weight management.
MOTS-c: A mitochondrial-derived peptide that regulates metabolic homeostasis and exercise mimetic.
Comparison Table
| Property | Tirzepatide | MOTS-c |
|---|---|---|
| Category | GLP-1/GIP Agonist | Metabolic & Longevity |
| Typical Dose | 2500-15000 mcg | 5000-10000 mcg |
| Frequency | 1x per week | 3-5x per week |
| Half-Life | ~5 days | Unknown |
| Timing | Same day each week, any time of day | Morning, preferably before exercise |
Tirzepatide Research
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist FDA-approved for Type 2 diabetes (Mounjaro) and weight management (Zepbound). Unlike semaglutide which only targets GLP-1, tirzepatide activates both GIP and GLP-1 receptors, providing enhanced metabolic benefits. Clinical trials (SURMOUNT) showed unprecedented weight loss results, with participants losing up to 22.5% of body weight - more than any other approved medication. It improves insulin sensitivity, reduces appetite, and may have additional benefits for fatty liver disease. The dual mechanism appears to provide superior efficacy compared to GLP-1 agonists alone.
Tirzepatide Full Guide | MOTS-c Full Guide | Dosage Calculator | Shop Peptides
For laboratory research use only. Not for human consumption.